BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Nordh S, Ansari D, Andersson R. hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: A systematic review. World J Gastroenterol 2014; 20(26): 8482-8490 [PMID: 25024604 DOI: 10.3748/wjg.v20.i26.8482]
URL: https://www.wjgnet.com/1007-9327/full/v20/i26/8482.htm
Number Citing Articles
1
Matthew J. Reilley, Gauri R. Varadhachary. Multimodality Management of Borderline Resectable Pancreatic Cancer2016; : 91 doi: 10.1007/978-3-319-22780-1_6
2
Stephanie E. Combs. Individualized radiotherapy (iRT) concepts for locally advanced pancreatic cancer (LAPC): indications and prognostic factorsLangenbeck's Archives of Surgery 2015; 400(7): 749 doi: 10.1007/s00423-015-1309-8
3
Lee Cheng Phua, Shixu Goh, David Wai Meng Tai, Wei Qiang Leow, Syed Muhammad Fahmy Alkaff, Chung Yip Chan, Juinn Huar Kam, Tony Kiat Hon Lim, Eric Chun Yong Chan. Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabineCancer Chemotherapy and Pharmacology 2018; 81(2): 277 doi: 10.1007/s00280-017-3475-6
4
Kombo F. N’Guessan, Harold W. Davis, Zhengtao Chu, Subrahmanya D. Vallabhapurapu, Clayton S. Lewis, Robert S. Franco, Olugbenga Olowokure, Syed A. Ahmad, Jen Jen Yeh, Vladimir Y. Bogdanov, Xiaoyang Qi. Enhanced Efficacy of Combination of Gemcitabine and Phosphatidylserine-Targeted Nanovesicles against Pancreatic CancerMolecular Therapy 2020; 28(8): 1876 doi: 10.1016/j.ymthe.2020.05.013
5
Qiqing Sun, Wenyan Xu, Shunrong Ji, Yi Qin, Wensheng Liu, Qiangsheng Hu, Zheng Zhang, Mengqi Liu, Xianjun Yu, Xiaowu Xu. Role of hepatocyte nuclear factor 4 alpha in cell proliferation and gemcitabine resistance in pancreatic adenocarcinomaCancer Cell International 2019; 19(1) doi: 10.1186/s12935-019-0767-4
6
Neal Bhutiani, Steven Agle, Yan Li, Suping Li, Robert C.G. Martin. Irreversible electroporation enhances delivery of gemcitabine to pancreatic adenocarcinomaJournal of Surgical Oncology 2016; 114(2): 181 doi: 10.1002/jso.24288
7
Mansi Arora, James M. Bogenberger, Amro Abdelrahman, Jennifer L. Leiting, Xianfeng Chen, Jan B. Egan, Aradhana Kasimsetty, Elzbieta Lenkiewicz, Smriti Malasi, Pedro Luiz Serrano Uson, Bolni Marius Nagalo, Yumei Zhou, Marcela A. Salomao, Heidi E. Kosiorek, Esteban Braggio, Michael T. Barrett, Mark J. Truty, Mitesh J. Borad. Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancerCancer Chemotherapy and Pharmacology 2020; 85(6): 1063 doi: 10.1007/s00280-020-04079-z
8
Hong-wei Yang, Guang-hui Liu, Yu-qiong Liu, Hong-chao Zhao, Zhen Yang, Chun-lin Zhao, Xie-fu Zhang, Hua Ye. Over-expression of microRNA-940 promotes cell proliferation by targeting GSK3β and sFRP1 in human pancreatic carcinomaBiomedicine & Pharmacotherapy 2016; 83: 593 doi: 10.1016/j.biopha.2016.06.057
9
S.-J. Cui, T.-Y. Tang, X.-W. Zou, Q.-M. Su, L. Feng, X.-Y. Gong. Role of imaging biomarkers for prognostic prediction in patients with pancreatic ductal adenocarcinomaClinical Radiology 2020; 75(6): 478.e1 doi: 10.1016/j.crad.2019.12.023
10
Kumiko Ueda, Ayasa Masuda, Misaki Fukuda, Shota Tanaka, Mika Hosokawa, Seigo Iwakawa. Monophosphorylation by deoxycytidine kinase affects apparent cellular uptake of decitabine in HCT116 colon cancer cellsDrug Metabolism and Pharmacokinetics 2017; 32(6): 301 doi: 10.1016/j.dmpk.2017.10.001
11
Justine M. Grixti, Steve O'Hagan, Philip J. Day, Douglas B. Kell. Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on GemcitabineFrontiers in Pharmacology 2017; 8 doi: 10.3389/fphar.2017.00155
12
Joseph Ciccolini, Cindy Serdjebi, Hau Le Thi Thu, Bruno Lacarelle, Gerard Milano, Raphaelle Fanciullino. Nucleoside analogs: ready to enter the era of precision medicine?Expert Opinion on Drug Metabolism & Toxicology 2016; 12(8): 865 doi: 10.1080/17425255.2016.1192128
13
Douglas B. Kell, Stephen G. Oliver. How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusionFrontiers in Pharmacology 2014; 5 doi: 10.3389/fphar.2014.00231
14
Jiawei Hong, Shiyun Xian, Shusen Zheng, Hangxiang Wang, Donghai Jiang. Addressing chemoresistance with a lipid gemcitabine nanotherapeutic strategy for effective treatment of pancreatic cancerNano Research 2024; 17(9): 8377 doi: 10.1007/s12274-024-6860-6
15
Marek Sierzega, Radosław Pach, Piotr Kulig, Janusz Legutko, Jan Kulig. Prognostic Implications of Expression Profiling for Gemcitabine-Related Genes (hENT1, dCK, RRM1, RRM2) in Patients With Resectable Pancreatic Adenocarcinoma Receiving Adjuvant ChemotherapyPancreas 2017; 46(5): 684 doi: 10.1097/MPA.0000000000000807
16
Larissa J. Vos, Dimas Yusuf, Arthur Lui, Zainab Abdelaziz, Sunita Ghosh, Jennifer L. Spratlin, John R. Mackey. Predictive and Prognostic Properties of Human Equilibrative Nucleoside Transporter 1 Expression in Gemcitabine-Treated Pancreatobiliary Cancer: A Meta-AnalysisJCO Precision Oncology 2019; (3): 1 doi: 10.1200/PO.18.00240
17
Hiroyuki Saito, Hiroshi Kashiyama, Takashi Murohashi, Kazunari Sasaki, Ryosuke Misawa, Susumu Ohwada. Case of Six-Year Disease-Free Survival with Undifferentiated Carcinoma of the PancreasCase Reports in Gastroenterology 2016; 10(2): 472 doi: 10.1159/000448878
18
Simona Mura, Elias Fattal, Julien Nicolas. From poly(alkyl cyanoacrylate) to squalene as core material for the design of nanomedicinesJournal of Drug Targeting 2019; 27(5-6): 470 doi: 10.1080/1061186X.2019.1579822
19
Lucie Jiraskova, Ales Ryska, Erik Jurjen Duintjer Tebbens, Helena Hornychova, Filip Cecka, Frantisek Staud, Lukas Cerveny. Are ENT1/ENT1, NOTCH3, and miR-21 Reliable Prognostic Biomarkers in Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Gemcitabine Monotherapy?Cancers 2019; 11(11): 1621 doi: 10.3390/cancers11111621
20
Radim Moravec, Rao Divi, Mukesh Verma. Detecting circulating tumor material and digital pathology imaging during pancreatic cancer progressionWorld Journal of Gastrointestinal Oncology 2017; 9(6): 235-250 doi: 10.4251/wjgo.v9.i6.235
21
Weiyun Huang, Xin Zeng, Yigong Shi, Minhao Liu. Functional characterization of human equilibrative nucleoside transporter 1Protein & Cell 2017; 8(4): 284 doi: 10.1007/s13238-016-0350-x
22
Girijesh Kumar Patel, Mohammad Aslam Khan, Arun Bhardwaj, Sanjeev K Srivastava, Haseeb Zubair, Mary C Patton, Seema Singh, Moh'd Khushman, Ajay P Singh. Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCKBritish Journal of Cancer 2017; 116(5): 609 doi: 10.1038/bjc.2017.18
23
Ornella Randazzo, Filippo Papini, Giulia Mantini, Alessandro Gregori, Barbara Parrino, Daniel S. K. Liu, Stella Cascioferro, Daniela Carbone, Godefridus J. Peters, Adam E. Frampton, Ingrid Garajova, Elisa Giovannetti. “Open Sesame?”: Biomarker Status of the Human Equilibrative Nucleoside Transporter-1 and Molecular Mechanisms Influencing its Expression and Activity in the Uptake and Cytotoxicity of Gemcitabine in Pancreatic CancerCancers 2020; 12(11): 3206 doi: 10.3390/cancers12113206
24
Rina Fujiwara-Tani, Takamitsu Sasaki, Tadataka Takagi, Shiori Mori, Shingo Kishi, Yukiko Nishiguchi, Hitoshi Ohmori, Kiyomu Fujii, Hiroki Kuniyasu. Gemcitabine Resistance in Pancreatic Ductal Carcinoma Cell Lines Stems from Reprogramming of Energy MetabolismInternational Journal of Molecular Sciences 2022; 23(14): 7824 doi: 10.3390/ijms23147824
25
Yue Yu, Fei Ding, Meng Gao, Yi Jia, Le Ren. Establishment and characterization of the gemcitabine‑resistant human pancreatic cancer cell line SW1990/gemcitabineOncology Letters 2019;  doi: 10.3892/ol.2019.10627
26
Mitsuru Okuno, Seiji Adachi, Osamu Kozawa, Masahito Shimizu, Ichiro Yasuda. The Clinical Significance of Phosphorylated Heat Shock Protein 27 (HSPB1) in Pancreatic CancerInternational Journal of Molecular Sciences 2016; 17(1): 137 doi: 10.3390/ijms17010137
27
Toshinori Ozaki, Meng Yu, Danjing Yin, Dan Sun, Yuyan Zhu, Youquan Bu, Meixiang Sang. Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutationsBMC Cancer 2018; 18(1) doi: 10.1186/s12885-018-4217-9
28
Ali Belkouz, Tim A. Labeur, Joeri Dierks, Frederike Dijk, Martijn G.H. van Oijen, Joanne Verheij, Thomas M. van Gulik, Marc J. van de Vijver, Hanneke Wilmink, Cornelis J.A. Punt, Heinz-Josef Klümpen. Prognostic immunohistochemical biomarkers of chemotherapy efficacy in biliary tract cancer: A systematic review and meta-analysisCritical Reviews in Oncology/Hematology 2019; 141: 82 doi: 10.1016/j.critrevonc.2019.06.001
29
Eugene J. Koay, Matthew H.G. Katz, Huamin Wang, Xuemei Wang, Laura Prakash, Milind Javle, Rachna Shroff, David Fogelman, Santiago Avila, Mohamed Zaid, Dalia Elganainy, Yeonju Lee, Christopher H. Crane, Sunil Krishnan, Prajnan Das, Jason B. Fleming, Jeffrey E. Lee, Eric P. Tamm, Priya Bhosale, Jeffrey H. Lee, Brian Weston, Anirban Maitra, Robert A. Wolff, Gauri R. Varadhachary. Computed Tomography–Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic CancerJCO Precision Oncology 2019; (3): 1 doi: 10.1200/PO.19.00001
30
Qiangsheng Hu, Yi Qin, Bo Zhang, Chen Liang, Shunrong Ji, Si Shi, Wenyan Xu, Jinfeng Xiang, Dingkong Liang, Quanxing Ni, Xianjun Yu, Jin Xu. FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1Oncology Reports 2017; 38(4): 2069 doi: 10.3892/or.2017.5856
31
Jaya Aseervatham, Lucky Tran, Khaled Machaca, Olga Boudker, Hernâni Gerós. The Role of Flexible Loops in Folding, Trafficking and Activity of Equilibrative Nucleoside TransportersPLOS ONE 2015; 10(9): e0136779 doi: 10.1371/journal.pone.0136779
32
Andrii Khomiak, Marius Brunner, Maximilian Kordes, Stina Lindblad, Rainer Christoph Miksch, Daniel Öhlund, Ivonne Regel. Recent Discoveries of Diagnostic, Prognostic and Predictive Biomarkers for Pancreatic CancerCancers 2020; 12(11): 3234 doi: 10.3390/cancers12113234
33
Balázs Vaskó, Viktória Juhász, Beáta Tóth, Anita Kurunczi, Zsolt Fekete, Joseph Krisjanis Zolnerciks, Emese Kis, Rémi Magnan, Axel Bidon-Chanal Badia, Marçal Pastor-Anglada, Eszter Hazai, Zsolt Bikadi, Ferenc Fülöp, Peter Krajcsi. Inhibitor selectivity of CNTs and ENTsXenobiotica 2019; 49(7): 840 doi: 10.1080/00498254.2018.1501832
34
Dunja Sobot, Simona Mura, Patrick Couvreur. How can nanomedicines overcome cellular-based anticancer drug resistance?Journal of Materials Chemistry B 2016; 4(30): 5078 doi: 10.1039/C6TB00900J
35
Cristiana Correia, Cristina P. R. Xavier, Diana Duarte, Abigail Ferreira, Sara Moreira, M. Helena Vasconcelos, Nuno Vale. Development of potent CPP6–gemcitabine conjugates against human prostate cancer cell line (PC-3)RSC Medicinal Chemistry 2020; 11(2): 268 doi: 10.1039/C9MD00489K
36
René J. Boosman, Marie-Rose B. S. Crombag, Nielka P. van Erp, Jos H. Beijnen, Neeltje Steeghs, Alwin D. R. Huitema. Is age just a number? A population pharmacokinetic study of gemcitabineCancer Chemotherapy and Pharmacology 2022; 89(5): 697 doi: 10.1007/s00280-022-04431-5
37
Jakob Kirkegård, Morten Ladekarl, Ida Ravnsbæk Johannsen, Frank Mortensen. Effect of adjuvant chemotherapy after pancreatectomy in patients with node-negative pancreatic cancer: target trial emulationBritish Journal of Surgery 2024; 111(1) doi: 10.1093/bjs/znad398
38
Daniel R. Principe, Patrick W. Underwood, Murray Korc, Jose G. Trevino, Hidayatullah G. Munshi, Ajay Rana. The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic EfficacyFrontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.688377
39
Dunja Sobot, Simona Mura, Semen O. Yesylevskyy, Laura Dalbin, Fanny Cayre, Guillaume Bort, Julie Mougin, Didier Desmaële, Sinda Lepetre-Mouelhi, Grégory Pieters, Bohdan Andreiuk, Andrey S. Klymchenko, Jean-Louis Paul, Christophe Ramseyer, Patrick Couvreur. Conjugation of squalene to gemcitabine as unique approach exploiting endogenous lipoproteins for drug deliveryNature Communications 2017; 8(1) doi: 10.1038/ncomms15678
40
Emmanouil Fokas, Eric O'Neill, Alex Gordon-Weeks, Somnath Mukherjee, W. Gillies McKenna, Ruth J. Muschel. Pancreatic ductal adenocarcinoma: From genetics to biology to radiobiology to oncoimmunology and all the way back to the clinicBiochimica et Biophysica Acta (BBA) - Reviews on Cancer 2015; 1855(1): 61 doi: 10.1016/j.bbcan.2014.12.001
41
M. Sinn, H. Riess, B.V. Sinn, J.M. Stieler, U. Pelzer, J.K. Striefler, H. Oettle, M. Bahra, C. Denkert, H. Bläker, P. Lohneis. Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine – Results from the CONKO-001 trialEuropean Journal of Cancer 2015; 51(12): 1546 doi: 10.1016/j.ejca.2015.05.005
42
Wei Wang, Xinzhe Yu, Hengchao Li, Chuanxin Yang, Chen Jin, Xinyu Huang. hENT1’s role in adjuvant intra-arterial gemcitabine-based chemotherapy for resectable pancreatic cancer patientsBMC Gastroenterology 2023; 23(1) doi: 10.1186/s12876-023-02666-x
43
Jianchun Xiao, Fangyu Zhao, Wenhao Luo, Gang Yang, Yicheng Wang, Jiangdong Qiu, Yueze Liu, Lei You, Lianfang Zheng, Taiping Zhang. Human Equilibrative Nucleoside Transporter 1: Novel Biomarker and Prognostic Indicator for Patients with Gemcitabine-Treated Pancreatic CancerCancer Management and Research 2024; : 651 doi: 10.2147/CMAR.S465098
44
Sharon D. Stoker, Zlata Novalić, Maarten A. Wildeman, Alwin D. R. Huitema, Sandra A. W. M. Verkuijlen, Hedy Juwana, Astrid E. Greijer, I. Bing Tan, Jaap M. Middeldorp, Jan Paul de Boer. Epstein–Barr virus-targeted therapy in nasopharyngeal carcinomaJournal of Cancer Research and Clinical Oncology 2015; 141(10): 1845 doi: 10.1007/s00432-015-1969-3
45
Christopher J. Endres, Aaron M. Moss, Kazuya Ishida, Rajgopal Govindarajan, Jashvant D. Unadkat. The role of the equilibrative nucleoside transporter 1 on tissue and fetal distribution of ribavirin in the mouseBiopharmaceutics & Drug Disposition 2016; 37(6): 336 doi: 10.1002/bdd.2015
46
Ruud H. Wijdeven, Baoxu Pang, Yehuda G. Assaraf, Jacques Neefjes. Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeuticsDrug Resistance Updates 2016; 28: 65 doi: 10.1016/j.drup.2016.07.001
47
Kanwal Baloch, Liqiong Chen, Ameer A Memon, Laura Dexter, William Irving, Mohammad Ilyas, Brian J Thomson. Equilibrative nucleoside transporter 1 expression in primary human hepatocytes is highly variable and determines uptake of ribavirinAntiviral Chemistry and Chemotherapy 2017; 25(1): 2 doi: 10.1177/2040206616686894
48
Tomas Koltai, Stephan Joel Reshkin, Tiago M. A. Carvalho, Daria Di Molfetta, Maria Raffaella Greco, Khalid Omer Alfarouk, Rosa Angela Cardone. Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic ReviewCancers 2022; 14(10): 2486 doi: 10.3390/cancers14102486
49
Akanksha Patel, Aishwarya Saraswat, Harsh Patel, Zhe-Sheng Chen, Ketan Patel. Palmitoyl Carnitine-Anchored Nanoliposomes for Neovasculature-Specific Delivery of Gemcitabine Elaidate to Treat Pancreatic CancerCancers 2022; 15(1): 182 doi: 10.3390/cancers15010182
50
Marie Sahlin, Monika Posaric Bauden, Roland Andersson, Daniel Ansari. Radioimmunotherapy—a potential novel tool for pancreatic cancer therapy?Tumor Biology 2015; 36(6): 4053 doi: 10.1007/s13277-015-3479-y
51
Ashwaq H.S. Yehya, Muhammad Asif, Amin M.S. Abdul Majid, Chern E. Oon. Complementary effects of Orthosiphon stamineus standardized ethanolic extract and rosmarinic acid in combination with gemcitabine on pancreatic cancerBiomedical Journal 2021; 44(6): 694 doi: 10.1016/j.bj.2020.05.015
52
Siyuan Zeng, Marina Pöttler, Bin Lan, Robert Grützmann, Christian Pilarsky, Hai Yang. Chemoresistance in Pancreatic CancerInternational Journal of Molecular Sciences 2019; 20(18): 4504 doi: 10.3390/ijms20184504
53
Ernest Osei, Christabel Oghinan, Akua Asare, Hillary Ho, Solomon Manful. Review of clinical and emerging biomarkers for early diagnosis and treatment management of pancreatic cancer: towards personalised medicineJournal of Radiotherapy in Practice 2022; 21(3): 421 doi: 10.1017/S1460396921000182
54
Sheng Chen, Ye Wang, Wen-Long Zhang, Mao-Sheng Dong, Jian-Hua Zhang. Sclareolide enhances gemcitabine-induced cell death through mediating the NICD and Gli1 pathways in gemcitabine-resistant human pancreatic cancerMolecular Medicine Reports 2017; 15(4): 1461 doi: 10.3892/mmr.2017.6182
55
Stefano Coppola, Ilaria Carnevale, Erik H.J. Danen, Godefridus J. Peters, Thomas Schmidt, Yehuda G. Assaraf, Elisa Giovannetti. A mechanopharmacology approach to overcome chemoresistance in pancreatic cancerDrug Resistance Updates 2017; 31: 43 doi: 10.1016/j.drup.2017.07.001
56
R. Nicolle, O. Gayet, M. Bigonnet, J. Roques, B. Chanez, F. Puleo, J. Augustin, J.F. Emile, M. Svrcek, T. Arsenijevic, P. Hammel, V. Rebours, M. Giovannini, P. Grandval, L. Dahan, V. Moutardier, E. Mitry, J.L. Van Laethem, J.B. Bachet, J. Cros, J. Iovanna, N.J. Dusetti. Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict adjuvant chemosensitivity in pancreatic cancerTranslational Oncology 2022; 16: 101315 doi: 10.1016/j.tranon.2021.101315
57
Praveen Bhoopathi, Padmanabhan Mannangatti, Swadesh K. Das, Paul B. Fisher, Luni Emdad. Pancreatic Cancer: Basic Mechanisms and TherapiesAdvances in Cancer Research 2023; 159: 285 doi: 10.1016/bs.acr.2023.02.010
58
Nikoleta Iosifidou, Eleni Anagnostopoulou, Maria Botou, Eirini Kalfa, Ekaterini Tatsaki, Stathis Frillingos. Elucidation of the Gemcitabine Transporters of Escherichia coli K-12 and Gamma-Proteobacteria Linked to Gemcitabine-Related ChemoresistanceInternational Journal of Molecular Sciences 2024; 25(13): 7012 doi: 10.3390/ijms25137012
59
Carlos Urey, Bodil Andersson, Daniel Ansari, Agata Sasor, Katarzyna Said-Hilmersson, Johan Nilsson, Roland Andersson. Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvant gemcitabineScandinavian Journal of Gastroenterology 2017; 52(5): 595 doi: 10.1080/00365521.2017.1290134
60
Mattia D. Pizzagalli, Ariel Bensimon, Giulio Superti‐Furga. A guide to plasma membrane solute carrier proteinsThe FEBS Journal 2021; 288(9): 2784 doi: 10.1111/febs.15531
61
R. Nicolle, O. Gayet, P. Duconseil, C. Vanbrugghe, J. Roques, M. Bigonnet, Y. Blum, N. Elarouci, L. Armenoult, M. Ayadi, A. de Reyniès, F. Puleo, J. Augustin, J.F. Emile, M. Svrcek, T. Arsenijevic, P. Hammel, M. Giovannini, P. Grandval, L. Dahan, V. Moutardier, M. Gilabert, J.L. Van Laethem, J.B. Bachet, J. Cros, J. Iovanna, N.J. Dusetti. A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinomaAnnals of Oncology 2021; 32(2): 250 doi: 10.1016/j.annonc.2020.10.601
62
Jiajia Li, Liyao Peng, Qun Chen, Ziping Ye, Tiantian Zhao, Sicong Hou, Jianguo Gu, Qinglei Hang. Integrin β1 in Pancreatic Cancer: Expressions, Functions, and Clinical ImplicationsCancers 2022; 14(14): 3377 doi: 10.3390/cancers14143377
63
Anteneh Tesfaye, Philip A. Philip. Textbook of Gastrointestinal Oncology2019; : 255 doi: 10.1007/978-3-030-18890-0_15
64
Steven Alexander Mann, Romil Saxena. Predictive Biomarkers in Oncology2019; : 437 doi: 10.1007/978-3-319-95228-4_40